Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Factors to consider when sequencing therapies in myeloma

Faith Davies • 26 Aug 2022
IMS 2022
Multiple Myeloma Antibodies BiTEs CAR-T

Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, shares some insights into the sequencing of immunotherapies in myeloma and important factors to consider, such as T-cell exhaustion and resistance mechanisms. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Faith Davies

Novel targets in multiple myeloma & the role of the immune system in disease progression 9:26
Novel targets in multiple myeloma & the role of the immune system in disease progression
Arun Wiita et al. • 12 Apr 2025
Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more
Faith Davies et al. • 4 Nov 2024
The potential for personalized medicine in high-risk myeloma 0:51
The potential for personalized medicine in high-risk myeloma
Faith Davies • 26 Sep 2024
Unmet needs in high-risk multiple myeloma & important factors to consider when treating patients 1:39
Unmet needs in high-risk multiple myeloma & important factors to consider when treating patients
Faith Davies • 26 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals